A detailed history of Affinity Asset Advisors, LLC transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 725,106 shares of ATXS stock, worth $6.74 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares
725,106
Previous 975,606 25.68%
Holding current value
$6.74 Million
Previous $8.88 Million 10.08%
% of portfolio
1.38%
Previous 1.21%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$8.97 - $12.65 $2.25 Million - $3.17 Million
-250,500 Reduced 25.68%
725,106 $7.98 Million
Q2 2024

Aug 14, 2024

BUY
$8.83 - $13.51 $1.15 Million - $1.76 Million
130,000 Added 15.37%
975,606 $8.88 Million
Q1 2024

May 14, 2024

SELL
$6.99 - $16.69 $4.34 Million - $10.4 Million
-620,859 Reduced 42.34%
845,606 $11.9 Million
Q4 2023

Feb 13, 2024

BUY
$4.42 - $8.06 $2.06 Million - $3.76 Million
466,165 Added 46.6%
1,466,465 $11.3 Million
Q3 2023

Nov 14, 2023

BUY
$6.89 - $9.86 $2.41 Million - $3.45 Million
349,425 Added 53.69%
1,000,300 $7.46 Million
Q2 2023

Aug 14, 2023

BUY
$8.33 - $13.72 $1.01 Million - $1.67 Million
121,506 Added 22.95%
650,875 $5.42 Million
Q1 2023

May 15, 2023

BUY
$11.2 - $15.79 $637,134 - $898,245
56,887 Added 12.04%
529,369 $7.04 Million
Q4 2022

Feb 13, 2023

BUY
$7.44 - $14.89 $538,946 - $1.08 Million
72,439 Added 18.11%
472,482 $7.04 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $10.34 $1.19 Million - $4.14 Million
400,043 New
400,043 $3.62 Million

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $141M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Affinity Asset Advisors, LLC Portfolio

Follow Affinity Asset Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.